Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease

Inclusion Criteria: 1\) Male and female patients aged 18 years or over 2\) i) Patients identified as eligible for treatment with either a PCSK9i or inclisiran ii) Patients diagnosed with moderate or severe calcific aortic stenosis based on non-enhanced Cardiac CT scan 3\) Willing and able to understand the Participant Information Sheet and provide informed consent 4\) The patient must agree to comply with the drawing of blood samples for the assessments 5\) The patient does not meet any of the exclusion criteria Exclusion Criteria: 1. Inability to provide valid informed consent 2. Male and female patients aged \< 18 years of age 3. The patient has, in the opinion of the investigator, significant neurological, hepatic, renal, endocrine, gastrointestinal, pulmonary, haemorrhagic, metabolic or other disease likely to confound the study requirements or analyses 4. The patient has a history of substance abuse or demonstrates signs or clinical features of active substance abuse or psychiatric disease 5. Alcohol consumption above recommended safe levels (i.e., more than 14 units per week) due to the potential effects of high alcohol levels on platelet reactivity 6. Any illness deemed significant by the investigator during the four (4) weeks preceding the screening period of the study 7. Any major bleeding diathesis or blood dyscrasia (platelets \< 70 x 109/l, Hb \< 8 g/dl, INR \> 1.4, APTT \> x 2 upper normal limit, leucocyte count \< 3.5 x 109/l, neutrophil count \< 1 x 109/l) 8. Currently enrolled in an investigational device or non-licensed drug trial